The company attributed its revenue drop to waning demand for its COVID-19 vaccine and said it will focus effort on its cancer pipeline.
Real Chemistry added that this marks the 21st consecutive year of double-digit top-line growth.
UK B2B arm delivered best results in a decade.
In contrast to the full-year topline growth, Syneos Health reported $1.3 billion in quarterly revenues, marking a 1% decrease.
Biogen said it expects “modest in-market revenue” for Leqembi in 2023, noting that commercialization expenses will exceed revenue.
Like Humira, Amjevita is approved for treating seven inflammatory diseases.
Pfizer said it expects a drop-off in revenues for its COVID-19 vaccines due to the federal government having a large supply on hand to start the year.
WPP was weakest performer among ‘big four’.
The healthcare specialist network reported 21% revenue growth in first half of the year.
The strong performance prompted UnitedHealth to boost its full-year earnings outlook.
MM+M is proud to announce the fourth annual Pinnacle Awards program, which celebrates the medical marketing industry’s most venerable marketers, strategists and creators.
Get the most out of
Register for free and enjoy unlimited access to:
